Wikia

Psychology Wiki

Phenoxybenzamine

Talk0
34,142pages on
this wiki
Revision as of 21:53, December 21, 2008 by Dr Joe Kiff (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


Phenoxybenzamine chemical structure
Phenoxybenzamine

benzyl(ethyl)(1-phenoxypropan-2-yl)amine
IUPAC name
CAS number
59-96-1
ATC code

C04AX02

PubChem
4768
DrugBank
APRD00651
Chemical formula {{{chemical_formula}}}
Molecular weight 303.826 g/mol
Bioavailability
Metabolism
Elimination half-life 24 hours
Excretion {{{excretion}}}
Pregnancy category C (U.S.)
Legal status
Routes of administration Oral

Phenoxybenzamine (marketed under the trade name Dibenzyline) is a non-specific, irreversible alpha blocker.

UsesEdit

It is used in the treatment of hypertension, and specifically that caused by pheochromocytoma. It has a slower onset and a longer lasting effect compared with other alpha blockers.

It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia,[1] although it is currently seldom used for that indication due to unfavourable side effects.

It has been used in the treatment of hypoplastic left heart syndrome.[2]

It is also used in Complex Regional Pain Syndrome Type 1 due to it's anti-adrenergic affects. It has shown to be beneficial if used in the first 3 months of CRPS diagnosis.

PharmacologyEdit

Phenoxybenzamine is used as an anti-hypertensive due to its efficacy in reducing the vasoconstriction caused by adrenaline and noradrenaline. Phenoxybenzamine forms a permanent covalent bond with adrenergic receptors. Based on what we know about the structures of these receptors, it likely involves attack by the cysteine at position 3.36 in transmembrane helix 3 to form a stable linkage.[3] Thus, it remains permanently bound to the receptor, preventing adrenaline and noradrenaline from binding. This causes vasodilatation in blood vessels, due to its antagonistic effect at the alpha-1 adrenoceptor found in the walls of blood vessels, resulting in a drop in blood pressure.

It will also affect the postsynaptic alpha 1 and 2 receptors in the nervous system, and so reduce sympathetic activity. This results in further vasodilation, pupil constriction, an increase in GI tract motility and secretions, and glycogen synthesis.

It also has partial agonist/antagonist properties at the serotonin 5-HT2A receptor.

ReferencesEdit

  1. Caine M, Perlberg S, Meretyk S (1978). A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. British journal of urology 50 (7): 551–4.
  2. Guzzetta NA (August 2007). Phenoxybenzamine in the treatment of hypoplastic left heart syndrome: a core review. Anesth. Analg. 105 (2): 312–5.
  3. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamäki A (2001). Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J. Biol. Chem. 276 (33): 31279–84.


Template:Peripheral vasodilators Template:Alpha blockers

This page uses Creative Commons Licensed content from Wikipedia (view authors).

Around Wikia's network

Random Wiki